Thromboembolic risk of carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for newly diagnosed multiple myeloma: A comparative systematic review and meta‐analysis

Ähnliche Einträge

• Health‐related quality of life in transplant‐eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient‐reported outcomes from GRIFFIN
  von: Rebecca Silbermann, et al.
  Veröffentlicht: (2024)
• Adverse impact of 1q amplification on outcomes in patients with multiple myeloma treated with daratumumab, carfilzomib and dexamethasone in a real‐world clinical setting
  von: Taku Kikuchi, et al.
  Veröffentlicht: (2024)
• Quadruplets in newly diagnosed transplant‐ineligible multiple myeloma
  von: Rajshekhar Chakraborty, et al.
  Veröffentlicht: (2024)
• The importance of autologous stem cell transplantation in improving outcomes in newly diagnosed patients with multiple myeloma
  von: Morie A. Gertz
  Veröffentlicht: (2024)
• Correction to “A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma ( CARAMEL )”
  Veröffentlicht: (2024)